1 / 8

UB Dept of Neurology UBMD Neurology/JNI

brains &GAINS November 2, 2013 9-12 a.m. Center For Tomorrow. UB Dept of Neurology UBMD Neurology/JNI. http://ubnjacobsneuro.wordpress.com/home/. https://www.facebook.com/UBMDNeurology. @ wolfegil. Gil I. Wolfe, MD. Irvin and Rosemary Smith Professor and Chair since Jan 2012

teal
Télécharger la présentation

UB Dept of Neurology UBMD Neurology/JNI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. brains&GAINS November 2, 2013 9-12 a.m. Center For Tomorrow UB Dept of Neurology UBMD Neurology/JNI http://ubnjacobsneuro.wordpress.com/home/ https://www.facebook.com/UBMDNeurology @wolfegil

  2. Gil I. Wolfe, MD • Irvin and Rosemary Smith Professor and Chair since Jan 2012 • 9 new Dept. of Neurology faculty • 3 stroke • 1 multiple sclerosis • 1 adult epilepsy • 1 child neurology • 1 neurocritical care • 2 neuroimaging (100% research) • Clinical and investigative career in neuromuscular medicine • Myasthenia Gravis (MG) • ECU-MG-301: Double-blind, placebo –controlled trial of eculizimab in refractory generalized MG • Clinical chair of international, NIH supported study of thymectomy in MG • Peripheral Neuropathy • GBS longitudinal follow-up study (IGOS) • Others • INSIGHTS • IV immunoglobulin usage patterns across U.S.

  3. Aging, Alzheimer’s Disease & Memory • Kinga Szigeti, MD, PhD • Director, Memory Disorders Program

  4. Disease Classification Motor neuron Neuronopathies & Neuropathies ALS, PLS, SMA, diabetic neuropathy, toxic neuropathy, GBS, CMT Axon Myelin Neuromuscular Junction Disorders MG, botulism NMJ Myopathies Muscular dystrophy, polymyositis, dermatomyositis, IBM Muscle

  5. Eculizimab in MG • Monoclonal antibody that binds complement C5, preventing cleavage to C5a • Complement activation is key component to damage of muscle membrane in MG • Cobra venom blocks complement and prevents induction of experimental autoimmune MG (EAMG) • Membrane attack complex (MAC) present on muscle membrane in EAMG animals and MG patients • Up to 10% of MG patients refractory

  6. MG and complement-mediated injury Control AChRAb MuSKAb MuSKAb • Shiraishi et al. Ann Neurol 2005;57:289 (biceps biopsies)

  7. Phase II Study of Eculizimab • n=14 (30-72 yrs) • AChRAb+ and failed 2 immunosuppressives, including prednisone, for ≥ 1 yr • No IVIg for 8 weeks or plasma exchange for 12 weeks • Results • Reduction by >3 QMG points during eculizimab vs. placebo marginally significant (p=0.0577) • Side effects • Mild to moderate • Nausea, back pain, headache, pharyngitis • 3 serious adverse advents on both active and placebo treatment Howard JF et al. Muscle Nerve 2013;48:76--84 600 mg IV qwk for 4 wks 900 mg IV at 5th q2wks for 12 wks

  8. ECU-MG-301: Eculizimab in refractory generalized MG • Phase 3, randomized (1:1), double-blinded, placebo-controlled trial • Treatment duration 26 wks • AChRAb+, age ≥ 18 yrs • MG-ADL score ≥ 6 • MG-ADL is the primary outcome measure • QMG, MGC, QOL also measured • Failed ≥2 immunotherapies for at least 1 yr • No IVIg or PE within 4 wks • Can continue on current immunosuppressive treatments without dose changes

More Related